Fasinumab

Fasinumab is a human monoclonal antibody designed for the treatment of pain, particularly osteoarthritis pain and chronic low back pain. It is developed by Regeneron Pharmaceuticals and Teva Pharmaceutical Industries.

Mechanism of Action[edit | edit source]

Fasinumab works by targeting and inhibiting nerve growth factor (NGF), a protein that plays a key role in the regulation of pain signals. By blocking NGF, Fasinumab can potentially reduce pain in patients with osteoarthritis and chronic low back pain.

Clinical Trials[edit | edit source]

Fasinumab has undergone several clinical trials to evaluate its safety and efficacy. In Phase II and III trials, Fasinumab demonstrated a significant reduction in pain and improved physical function in patients with osteoarthritis of the knee or hip. However, the trials also revealed a higher rate of joint-related adverse events in Fasinumab-treated patients compared to placebo.

Potential Side Effects[edit | edit source]

The most common side effects of Fasinumab include joint swelling, pain, and peripheral edema. Serious side effects may include joint destruction, which can lead to the need for joint replacement surgery.

Current Status[edit | edit source]

As of 2021, Fasinumab is still under investigation and has not yet been approved by the Food and Drug Administration (FDA) for use in the United States.

See Also[edit | edit source]

Fasinumab Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.